CSRXP STATEMENT ON CONFIRMATION OF RFK JR AS SECRETARY OF U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Campaign Looks Forward to Working with Kennedy and the Administration to Lower Prescription Drug Prices for American Consumers

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement on Thursday, February 13 following the U.S. Senate confirmation of Robert F. Kennedy Jr. to serve as Secretary of the U.S. Department of Health and Human Services (HHS).

“CSRxP congratulates Secretary Kennedy on his confirmation and looks forward to working with HHS under his leadership, and the entire administration, to advance our shared objective of lowering prescription drug prices for the American people,” said CSRxP spokesman Jon Conradi. “Secretary Kennedy has expressed interest in several longstanding areas of focus for CSRxP, including fostering greater competition in the prescription drug marketplace by cracking down on Big Pharma’s patent abuse and exercising greater scrutiny over brand name manufacturers’ massive spending on direct-to-consumer (DTC) advertising for blockbuster products. We welcome the opportunity to be a resource for Secretary Kennedy and the administration on these, and additional drivers of high prescription drug prices in America, to improve affordability and value for American patients.”

Read more about Big Pharma’s out-of-control drug prices HERE and patent abuse HERE.

Read more on Big Pharma’s DTC advertising HERE.

Read more on bipartisan, market-based solutions to hold Big Pharma accountable HERE.

###